drugset / Trial / NCT06402513

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

NCT06402513

Phase 1 Completed 12 enrolled AbbVie
NaSingle-groupOpen-labelBasic science

Summary

The objective of this study is to assess the pharmacokinetics, immunogenicity, safety, and tolerability, of subcutaneous formulation of ravagalimab in a pre-filled syringe in healthy adult participants.

Timeline

Start
2024-06-24
Primary completion
2024-10-08
Completion
2024-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravagalimab Monoclonal antibody Subcutaneous

Indications

No indication recorded.